How to Get Rapamycin (Sirolimus) in California

Who Can Prescribe Rapamycin in California

Any California-licensed MD or DO can write a rapamycin prescription for on-label or off-label use. Nurse practitioners and physician assistants can also prescribe sirolimus under California's scope-of-practice statutes, though NPs must follow a standardized procedure agreement if they hold a non-furnishing license, and PAs prescribe under a supervising physician per CA Business & Professions Code §3502.1.

MDs, DOs, and Longevity-Focused Clinicians

Most off-label rapamycin prescriptions in California come from longevity medicine physicians, anti-aging specialists, or functional medicine doctors. The FDA approved sirolimus in 1999 for renal transplant rejection prophylaxis [1], and physicians may legally prescribe it off-label when clinical judgment supports the decision. A 2023 survey in the journal GeroScience found that over 5,000 U.S. Adults were estimated to use rapamycin off-label for aging-related purposes [2].

Telehealth Prescribers

California law permits telehealth prescribing of non-controlled medications, including sirolimus. Under CA Business & Professions Code §2290.5, a physician-patient relationship can be established via synchronous video visit. Several telehealth platforms now specialize in longevity prescriptions, and patients can complete the entire consultation, lab review, and prescription process remotely.

The California Medical Board requires that telehealth prescribers maintain the same standard of care as in-person visits [3]. This means a telehealth physician must still review labs, assess contraindications, and document the clinical rationale for off-label use.

Required Labs Before Starting Rapamycin

Prescribers in California follow a lab protocol similar to what transplant centers use, adapted for lower-dose longevity regimens. Labs serve two purposes: ruling out contraindications and establishing a baseline for monitoring.

Baseline Panel

Before writing the first prescription, most clinicians order a complete blood count (CBC), comprehensive metabolic panel (CMP), fasting lipid panel, hemoglobin A1c, and fasting glucose. Rapamycin inhibits mTOR signaling, which can raise fasting glucose and LDL cholesterol. In the PEARL trial (N=30, median age 68), participants receiving 5 mg weekly rapamycin showed a mean 9.6% increase in LDL cholesterol after 12 months [4]. Baseline lipid values help clinicians decide whether a statin or dose adjustment is warranted before initiation.

Immunologic and Hepatic Screening

Because sirolimus has immunosuppressive properties at higher doses, some prescribers also check hepatitis B surface antigen, hepatitis C antibody, and a tuberculosis screen (QuantiFERON-TB Gold or PPD). The FDA-approved prescribing information for Rapamune warns against use in patients with active infections [5]. Liver function tests (AST, ALT, bilirubin) are standard because sirolimus is metabolized by CYP3A4 in the liver [6].

Follow-Up Lab Schedule

Most longevity clinicians recheck CBC, CMP, and lipids at 6 to 8 weeks after initiation, then every 3 to 6 months. Trough-level monitoring, standard in transplant medicine (target 4 to 12 ng/mL for renal graft recipients per KDIGO guidelines), is not always performed in once-weekly off-label regimens because intermittent dosing produces lower and more transient peak levels [7].

How to Fill a Rapamycin Prescription in California

California offers two main pharmacy pathways for sirolimus: retail pharmacies dispensing FDA-approved tablets, and 503A compounding pharmacies preparing custom formulations.

FDA-Approved Generic Tablets

Sirolimus is available as FDA-approved 0.5 mg, 1 mg, and 2 mg tablets manufactured by Pfizer (Rapamune) and several generic manufacturers including Greenstone and Zydus. Retail pharmacies (CVS, Walgreens, Rite Aid, independent pharmacies) can fill prescriptions for generic sirolimus. GoodRx data from May 2026 show generic sirolimus 1 mg (30 tablets) priced between $30 and $90 at California retail pharmacies, depending on the pharmacy and discount card used.

503A Compounding Pharmacies

California's Board of Pharmacy licenses 503A compounding pharmacies under CA Business & Professions Code §4127. These pharmacies can prepare custom sirolimus capsules (for example, 5 mg or 6 mg capsules for once-weekly dosing) when a prescriber writes a patient-specific prescription. 503A pharmacies in California can ship within the state and, under certain conditions, to patients in other states where reciprocity agreements exist.

A compounded 5 mg sirolimus capsule from a California 503A pharmacy typically costs $3 to $8 per capsule, making a once-weekly regimen roughly $12 to $32 per month. This is often less expensive than splitting or combining multiple FDA-approved tablets.

Shipping and Delivery Timelines

Retail pharmacy fills for generic sirolimus usually take 1 to 3 business days if the drug is in stock. Compounding pharmacies require 3 to 7 business days for preparation and ship via cold chain or standard packaging depending on the formulation. Total time from prescription to delivery ranges from 3 to 10 business days for most California patients.

Insurance Coverage and Prior Authorization in California

Coverage for sirolimus varies sharply based on the indication and the insurance plan.

Medi-Cal (California Medicaid)

Medi-Cal covers sirolimus for its FDA-approved indication (prevention of organ transplant rejection) with prior authorization. The PA request must include documentation of the transplant procedure, current immunosuppressive regimen, and lab results confirming graft function. Off-label longevity use is not covered by Medi-Cal. The Department of Health Care Services (DHCS) publishes its formulary and PA criteria through the Medi-Cal Rx program [8].

Commercial Insurance

Most commercial plans in California (Blue Shield, Anthem Blue Cross, Kaiser Permanente, Health Net) cover sirolimus for transplant rejection. Off-label prescriptions typically require a peer-to-peer review or a letter of medical necessity. A 2022 JAMA Network Open analysis found that off-label prescriptions account for approximately 20% of all U.S. Outpatient prescriptions, with insurer approval rates varying between 30% and 60% depending on the drug and indication [9].

Prior Authorization Documentation

PA requests for sirolimus in California generally require: diagnosis code (Z94.0 for kidney transplant, or the relevant ICD-10 code), prescriber NPI, patient lab results (renal function, CBC), letter of medical necessity for off-label use, and documentation that the patient has tried or considered alternative therapies. The turnaround for PA decisions in California is 24 hours for urgent requests and up to 5 business days for standard requests under CA Health & Safety Code §1367.241 [10].

Clinical Evidence for Off-Label Rapamycin Use

The growing interest in rapamycin prescriptions in California stems from preclinical and early clinical data on mTOR inhibition and aging.

Preclinical Lifespan Data

Rapamycin extended median lifespan by 9% in male mice and 14% in female mice in the National Institute on Aging Interventions Testing Program (ITP), even when treatment started at 20 months of age (equivalent to roughly 60 human years) [11]. This 2009 study, published in Nature, remains the most replicated pharmacologic lifespan extension in mammals. Subsequent ITP replications confirmed the finding across three independent sites [12].

The PEARL Trial

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial, published in Aging Cell in 2024, enrolled 30 healthy adults aged 50 to 85 years. Participants received sirolimus 5 mg weekly for 12 months. The primary endpoint was change in visceral abdominal fat measured by DEXA scan. Results showed a non-significant trend toward reduced visceral fat, with secondary endpoints showing favorable changes in bone mineral density at the lumbar spine (+1.2% vs. Baseline) [4]. The trial confirmed that weekly low-dose rapamycin was well-tolerated, with the most common adverse events being mouth sores (10%) and mild upper respiratory infections (13%).

Immune Function Studies

A randomized controlled trial by Mannick et al. (2014) in Science Translational Medicine gave healthy elderly volunteers (age ≥65) the mTOR inhibitor everolimus (a rapamycin analog) at 0.5 mg daily for 6 weeks before influenza vaccination. The treatment group showed a 20% improvement in antibody response to influenza compared to placebo [13]. A follow-up study by the same group (2018) using a combination of mTOR inhibitors in 264 elderly subjects confirmed enhanced immune response and a 30.6% reduction in respiratory tract infections over one year [14].

Ongoing Trials

The VALIDATING trial and the Dog Aging Project's rapamycin arm are collecting data on rapamycin's effects on aging biomarkers in humans and companion animals, respectively. Results from these larger trials may shift the risk-benefit calculus for off-label prescribing over the next 2 to 4 years [15].

Safety Considerations and Contraindications

Rapamycin is not a benign supplement. It is a potent immunosuppressant at transplant doses, and even weekly low-dose regimens require clinical oversight.

Common Side Effects at Low Doses

Mouth ulcers (aphthous stomatitis) are the most frequently reported side effect in off-label users. The PEARL trial reported oral ulcers in 10% of participants at 5 mg weekly [4]. Other reported effects include mild dyslipidemia (elevated LDL and triglycerides), transient hyperglycemia, and delayed wound healing. The FDA label for Rapamune lists a comprehensive adverse event profile derived from transplant populations receiving daily doses of 2 to 5 mg [5].

Contraindications

Sirolimus is contraindicated in patients with known hypersensitivity to the drug, active serious infections, and pregnancy (FDA Pregnancy Category C). The FDA label warns of increased susceptibility to infection and possible development of lymphoma, consistent with immunosuppressive therapy in general [5]. Patients with baseline hyperlipidemia (LDL >190 mg/dL) or uncontrolled diabetes (HbA1c >9%) should use rapamycin only with careful monitoring and concurrent management of these conditions [16].

Drug Interactions

Sirolimus is metabolized by CYP3A4 and is a substrate of P-glycoprotein. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, grapefruit juice) significantly increase sirolimus blood levels. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) decrease levels [6]. The FDA label recommends monitoring sirolimus trough concentrations when co-administered with CYP3A4 modulators [5].

Transferring a Rapamycin Prescription to California

Patients relocating to California or visiting from another state can transfer an existing sirolimus prescription. California Board of Pharmacy regulations allow prescription transfers between licensed pharmacies, including interstate transfers. The receiving pharmacy contacts the originating pharmacy, verifies the prescription, and dispenses the remaining refills.

For compounded sirolimus, patients may need a new prescription from a California-licensed prescriber, since 503A compounding requires a patient-specific prescription and the compounding pharmacy must be licensed in California. A telehealth visit with a California-licensed physician can generate a new prescription within 24 to 48 hours [17].